Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 14/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | GC | P02774 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379816 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL8773164 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL7154542 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL25310518 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL5385262 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL5680998 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL5378950 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL7151478 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL8527611 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL5390580 | 0.90 | VDR (0.47) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065886-A1 | METHOD FOR PRODUCING MAXACALCITOL, AND INTERMEDIATE THEREFOR | YONSUNG FINE CHEMICAL CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
| WO-2021107646-A1 | METHOD FOR PRODUCING MAXACALCITOL, AND INTERMEDIATE THEREFOR | 연성정밀화학(주) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065886-A1 | METHOD FOR PRODUCING MAXACALCITOL, AND INTERMEDIATE THEREFOR | SI, DCXR, CYP51A1 | VDR 2277/4885MAPT 3204/4885ADORA3 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.